Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) due to potential product carton strength mislabeling.
Similar Posts
Face Rock Creamery LLC Recalls 6oz. Vampire Slayer Garlic Cheddar Because of Possible Health Risk
November 14, 2025, Face Rock Creamery LLC of Bandon, OR is voluntarily recalling 16/6oz. units of Vampire Slayer Garlic Cheddar with a use-by date of 11/04/26 because it has the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infectioSHATA TRADERS INC RECALLS CHEF BRAND MILK PAN 24cm BECAUSE OF POSSIBLE HEALTH RISK
Shata Traders Inc of Brooklyn, NY is recalling Chef Brand Milk Pan 24 cm, because it has the potential to be contaminated with significant levels of lead (Pb) which may leach into food. Lead is toxic to humans and can affect people of any age or health status, and there is no known safe level of expFDA Grand Rounds – Anti-biofilm Technologies for Enhancing the Safety of Medical Device Surfaces – 05/29/2025
Anti-biofilm Technologies for Enhancing the Safety of Medical Device Surfaces, May 29, 2025.Savannah Bee Company Recalls Honey BBQ Sauce-Mustard Due to Undeclared Wheat and Soy
SAVANNAH, GA 2-27-2026 – Savannah Bee Company is recalling their HONEY BBQ SAUCE- MUSTARD, 16FL OZ B1L1360525 Best Before 05/16/27 UPC 8 50033 93758 9 due undeclared wheat and soy. People who have an allergy or severe sensitivity to wheat or soy run the risk of serious or life-threatening allergic r“Peter Michael, M.D. – 711299 – 06/18/2025
Clinical InvestigatorFDA In Brief: FDA issues draft guidance to foster oncology product development for pediatric populations
FDA issues draft guidance document, “FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act.” The draft guidance addresses early planning for pediatric evaluation of certain molecularly targeted oncology drugs.
